About Us
2021
- GoldenBiotech will publish the abstract of the Phase 2 clinical trial results and progress of AML(Acute Myeloid Leukemia) in 2021 ASCO Meeting.
- Covid-19 Drug Duo Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries.
- GoldenBiotech was Granted the Patent for “Methods and compositions for treating arteriosclerotic vascular diseases” by European Patent Office.
2020
- Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia.
- BIO Asia Taiwan 2020 Exhibition Highlights-“GoldenBiotech Can Help!” Featuring Progress of Antroquinonol on COVID-19 Phase 2 Trial in USA.
- The Associated Press- Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA.
- Bloomberg- Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA.
- Anti-viral and Anti-Inflammatory Response: GoldenBiotech’s Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA.
- GoldenBiotech’s Antroquinonol Completed Phase 1 Trial and Started Phase 2 for Metastatic Pancreatic Cancer as First Line Treatment.
2019
- USA National Institutes of Health (NIH)- National Cancer Institute(NCI) Listed the term of drug name: Antroquinonol ( HOCENA).
- GoldenBiotech Antroquinonol Phase 2 NSCLC Clinical Study Presents Brilliant Results in ASCO Meeting.
- Golden Biotechnology Corp. Starts Phase 2 Trial for Efficacy of Antroquinonol in AML after Russian MOH Approval.
2018
- Golden Biotechnology Corp. was Granted the Patent for Treating Fatty Liver Diseases by the European Patent Office.
- Golden Biotechnology Corp. Met Targets in Clinical Trial of Antroquinonol for Hypercholesterolemia and Hyperlipidemia.
2017
- European Commission has issued the Commission Implementing Decision that Antroquinonol is designated as an orphan medicinal product for the indication of treating pancreatic cancer.
2016
- Golden Biotechnology Corp.’s New Drug Hocena for treating of cancer and hyperlipidemia won National Innovation Award in Taiwan.
- Golden Biotechnology Corp. won the Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge Award with potential treatment for Alzheimer’s disease.
2015
- Golden Biotechnology Corp. was granted 3 orphan drug designations for the treatment of pancreatic cancer , acute myeloid leukemia (AML) and liver cancer by US FDA.
2014
- Antroquinonol® acquired patent「Methods and compositions for treating cancer metastasis」, patent No. US 8,648,117 B2.
2013
- Winner of the 3rd National Industrial Innovation Award by MOEA, R.O.C
- Winner of Top 10 Outstanding Enterprises & Winner of Top 10 Outstanding Innovation and Leadership at the 15th Golden Peak Awards
2012
- Winner of Top 10 Outstanding Enterprise by OEMA, R.O.C
- Winner of Top 10 Outstanding Manager by OEMA, R.O.C
2009
2008
- National Health Food Certificate for liver protection issued by Department of Health, Taiwan. (License #00124)
- National Biotechnology and Medical Care Quality Award and the Silver Prize, Taiwan.
2007
- National Innovation Award in the Innovative Technology Category for Biotechnology and Medicine Industry, Taiwan.
- Symbol of National Quality in Health Food Category by Institute for Biotechnology and Medicine Industry, Taiwan